» Articles » PMID: 25256937

Ovarian Response to Recombinant Human Follicle-stimulating Hormone: a Randomized, Antimüllerian Hormone-stratified, Dose-response Trial in Women Undergoing in Vitro Fertilization/intracytoplasmic Sperm Injection

Overview
Journal Fertil Steril
Date 2014 Sep 27
PMID 25256937
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the dose-response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study the influence of initial antimüllerian hormone (AMH) concentrations.

Design: Randomized, controlled, assessor-blinded, AMH-stratified (low: 5.0-14.9 pmol/L [0.7-<2.1 ng/mL]; high: 15.0-44.9 pmol/L [2.1-6.3 ng/mL]) trial.

Setting: Seven infertility centers in four countries.

Patient(s): Two hundred sixty-five women aged ≤37 years.

Intervention(s): Controlled ovarian stimulation with either 5.2, 6.9, 8.6, 10.3, or 12.1 μg of rhFSH, or 11 μg (150 IU) of follitropin alfa in a GnRH antagonist cycle.

Main Outcome Measure(s): Number of oocytes retrieved.

Result(s): The number of oocytes retrieved increased in an rhFSH dose-dependent manner, from 5.2 ± 3.3 oocytes with 5.2 μg/d to 12.2 ± 5.9 with 12.1 μg/d. The slopes of the rhFSH dose-response curves differed significantly between the two AMH strata, demonstrating that a 10% increase in dose resulted in 0.5 (95% confidence interval 0.2-0.7) and 1.0 (95% confidence interval 0.7-1.3) more oocytes in the low and high AMH stratum, respectively. Fertilization rate and blastocyst/oocyte ratio decreased significantly with increasing rhFSH doses in both AMH strata. No linear relationship was observed between rhFSH dose and number of blastocysts overall or by AMH strata. Five cases of ovarian hyperstimulation syndrome were reported for the three highest rhFSH doses and in the high AMH stratum.

Conclusion(s): Increasing rhFSH doses results in a linear increase in number of oocytes retrieved in an AMH-dependent manner. The availability of blastocysts is less influenced by the rhFSH dose and AMH level.

Clinical Trial Registration Number: NCT01426386.

Citing Articles

Controlled ovarian stimulation (COS) with follitropin delta results in higher cumulative live birth rates compared with follitropin alfa/beta in a large retrospectively analyzed real-world data set.

Eggersmann T, Schutt M, Becker J, Kimmel M, Aust H, Winkler J Reprod Biol Endocrinol. 2025; 23(1):25.

PMID: 39980039 PMC: 11841343. DOI: 10.1186/s12958-025-01364-5.


Optimizing oocyte yield utilizing a machine learning model for dose and trigger decisions, a multi-center, prospective study.

Canon C, Leibner L, Fanton M, Chang Z, Suraj V, Lee J Sci Rep. 2024; 14(1):18721.

PMID: 39164339 PMC: 11335759. DOI: 10.1038/s41598-024-69165-1.


Verification of the utility of the gonadotropin starting dose calculator in progestin-primed ovarian stimulation: A comparison of empirical and calculated controlled ovarian stimulation.

Kobanawa M, Yoshida J Reprod Med Biol. 2024; 23(1):e12586.

PMID: 38827517 PMC: 11140174. DOI: 10.1002/rmb2.12586.


BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle.

Lobo R, Soerdal T, Ekerhovd E, Cohlen B, Porcu E, Schenk M Hum Reprod. 2024; .

PMID: 38723189 PMC: 11759129. DOI: 10.1093/humrep/deae092.


Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.

Palomba S, Caserta D, Levi-Setti P, Busnelli A J Ovarian Res. 2024; 17(1):60.

PMID: 38486276 PMC: 10938807. DOI: 10.1186/s13048-024-01372-w.